Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAMA-6 SAD/MAD Study in Healthy Adults
NCT06300398Phase 1Completed
- Sponsor
- IAMA Therapeutics
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IAMA-6 in neurodevelopmental disorders (NDDs), sponsored by IAMA Therapeutics. Primary endpoints: Adverse Events at 1 year, Serious Adverse Events at 1 year and 5 more. Started Jan 2024; status: completed.
02
Drugs
IAMA-6
03
Conditions
neurodevelopmental disorders (NDDs)
Beyond the preview
Go deeper on NCT06300398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06300398.